First order of the Risk Committee business:
- set timeframe for PR to relinquish his dual roles
- risk assess existing teams ability to coordinate +120 clinical sites for P3 including timeframes, standardisation of treatment scripting delivery to manage placebo
- mandatory vetting of ASX releases for inconsistency from risk and legal experts
- establish tracking log for key milestones and publicly stated prior committeements eg peer reviews
- review Board and Exec REM benchmarking to confirm independence of source
- Hire a Board member with actual risk and compliance experience that is capable of standing their ground and not forced to move on under false pretences
- Etc etc etc
PAR. SP, page-953
-
- There are more pages in this discussion • 300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 143324 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 44935 | 3 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |